Zenas BioPharma (ZBIO) Non-Current Assets (2023 - 2026)

Zenas BioPharma's Non-Current Assets history runs 4 years deep, the most recent figure standing at $17.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 9.77% year-over-year to $17.5 million in Q1 2026; TTM through Mar 2026 was $89.8 million, a 87.04% increase from a year earlier, with the FY2025 full-year figure at $32.5 million, up 131.18% from the prior year.
• Non-Current Assets eased to $17.5 million in Q1 2026 per ZBIO's latest filing, from $32.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $32.5 million in Q4 2025 and bottomed at $8.4 million in Q4 2023.
• The 4-year median for Non-Current Assets is $15.2 million (2025), against an average of $17.2 million.
• Across the five-year window, Non-Current Assets soared 162.85% in 2025 and increased 9.77% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $8.4 million in 2023, then jumped by 67.68% to $14.0 million in 2024, then soared by 131.18% to $32.5 million in 2025, then plunged by 46.05% to $17.5 million in 2026.
• Per Business Quant, the three latest ZBIO Non-Current Assets figures stand at $17.5 million (Q1 2026), $32.5 million (Q4 2025), and $25.4 million (Q3 2025).